Novartis Ag NVS
NYSE NVS
$158.86 +2.62 (+1.68%)
At close: Aug 21, 2026 · 4:00 PM EDT

Novartis Ag (NVS) Income towards Parent Company (2009 - 2026)

Novartis Ag (NVS) posted Income towards Parent Company of $3.3 billion for Q2 2026, down 92.23% sequentially from $42.0 billion in Q2 2025, and down 92.23% YoY from $42.0 billion in Q2 2025.

Novartis Ag (NVS) Income towards Parent Company (2009 - 2026) Analysis & Trends

Novartis Ag has reported Income towards Parent Company for 18 years, with the latest figure at $3.3 billion in Q2 2026.

  • Quarterly Income towards Parent Company fell 92.23% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (down 92.23% YoY) and the FY2025 annual result came in at $14.0 billion, down 68.25% from the prior year.
  • Income towards Parent Company fell to $3.3 billion in Q2 2026 per NVS's latest filing, from $42.0 billion in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $34001.4 billion in Q1 2022 and troughed at $144.0 million in Q1 2023.
  • A 5-year average of $2862.8 billion and a median of $43.0 billion in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company surged 142.84% in 2022, then plunged 100.0% in 2023.
  • Over 5 years, Income towards Parent Company stood at $59.3 billion in 2022, then retreated by 21.36% to $46.7 billion in 2023, then dropped by 5.62% to $44.0 billion in 2024, then dropped by 4.68% to $42.0 billion in 2025, then plunged by 92.23% to $3.3 billion in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $3.3 billion, $42.0 billion, and $44.0 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 3.26 Bn
Jun 30, 2025 41.99 Bn
Dec 31, 2024 44.05 Bn
Jun 30, 2024 41.73 Bn
Dec 31, 2023 46.67 Bn
Sep 30, 2023 250.00 Mn
Jun 30, 2023 51.85 Bn
Mar 31, 2023 144.00 Mn
Dec 31, 2022 59.34 Bn
Sep 30, 2022 245.00 Mn
Jun 30, 2022 62.93 Bn
Mar 31, 2022 34,001.37 Bn
Dec 31, 2021 67.66 Bn
Sep 30, 2021 1.40 Bn
Jun 30, 2021 54.04 Bn
Mar 31, 2021 14,001.31 Bn
Dec 31, 2020 56.60 Bn
Sep 30, 2020 18,001.39 Bn
Jun 30, 2020 53.81 Bn
Mar 31, 2020 194.00 Mn